menu
    • menu
    [{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"LoQus23 Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LoQus23 Therapeutics \/ Dementia Discovery Fund","highestDevelopmentStatusID":"2","companyTruncated":"LoQus23 Therapeutics \/ Dementia Discovery Fund"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LoQus23 Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LoQus23 Therapeutics \/ Forbion","highestDevelopmentStatusID":"14","companyTruncated":"LoQus23 Therapeutics \/ Forbion"}]

    Find Clinical Drug Pipeline Developments & Deals by LoQus23 Therapeutics

    Menu

    LoQus23 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LoQus23 Therapeutics

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            LoQus23 Therapeutics

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Forbion

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LoQus23 Secures £35M to Advance Small Molecule Therapy for Huntington's Disease

                            Details : The proceeds from the financing will be primarily used to support the pre-clinical development and initial clinical studies of LoQus23's lead program, an allosteric small molecule MutSβ inhibitor.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Forbion

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LoQus23 Therapeutics

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            LoQus23 Therapeutics

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Dementia Discovery Fund

                            Deal Size : $9.4 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LoQus23 Therapeutics Exits Stealth with £11.5 Million Seed Financing From the Dementia Discovery Fund and Nov...

                            Details : The financing will enable LoQus23 to identify a small molecule drug candidate for the company's lead MMR target and explore other MMR proteins for their role in somatic instability in TRDs.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 23, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Dementia Discovery Fund

                            Deal Size : $9.4 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth